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Summary The aim of this study was to investigate certain genes for their suitability as molecular markers for detection of breast carcinoma
cells using the reverse transcriptase-polymerase chain reaction (RT-PCR). RNA was prepared from MCF-7 breast carcinoma cells and
peripheral blood leucocytes of healthy female volunteers. This RNA was screened for mRNA of MUC1, cytokeratin 19 (CK19) and CD44
(exons 8-11) by RT-PCR and the results validated by Southern blots. Variable degrees of expression of MUC1 and CD44 (exons 5-11) were
detected in normal peripheral blood, rendering these genes non-specific for epithelial cells and therefore unsuitable for use as markers to
detect breast carcinoma cells. Although CK19 mRNA was apparently specific, it was deemed unsuitable for use as a markerof breast cancer
cells in light of its limited sensitivity. Furthermore, an attempt at using nested primers to increase sensitivity resulted in CK19 mRNA being
detected after two amplification rounds in blood from healthy volunteers.
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Breast cancer is a significant world-wide public health problem.
The lifetime riskofa womandeveloping breastcanceris 1 in 8 and
the risk ofdying from disseminated disease is 1 in 30 (Feuer et al,
1993). Despite major advances in adjuvant therapy, improvement
in survival has been disappointingly small. Targeting patients
appropriately for adjuvant therapy is currently based on clinico-
pathological prognostic factors. Recent interest has focused on
developing laboratory methods to identify disseminated tumour
cells in the circulation. This may identify a subgroup of patients
suitable for adjuvant systemic therapy.
Several workers have attempted to identify circulating tumour
cells in various malignancies (Smith et al, 1991; Burchill et al,
1994; Brown et al, 1995; Burchill et al, 1995; McCulloch et al,
1995; Choy and McCulloch, 1996). Various techniques, including
morphology, flow cytometry and cytogenetics, have been used to
detect disseminated tumour cells, but most of these have limited
sensitivity and specificity (Frank et al, 1990; Diel et al, 1992;
Johnson et al, 1995) and are time-consuming (Gross et al, 1995).
Immunocytochemistry has also been used in an attempt to detect
circulating breast carcinoma cells perioperatively, but sensitivity
remains a concern with this technique (McCulloch et al, 1995;
Choy and McCulloch, 1996).
Reverse transcriptase-polymerase chain reaction (RT-PCR) is a
newer approach to detect circulating tumour cells. Tumour-specific
DNA sequence abnormalities havebeen identified mainlyinhaema-
tological malignancies, such as acute lymphoblastic leukaemia, for
which this technique has been used in the diagnosis and follow-up
of patients (Yamada et al, 1990; Steward et al, 1994). For solid
tumours, however, tumour-specific DNA sequence abnormalities
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are uncommon and, consequently, putative tissue-specific mRNAs
have been used as molecular markers to detect circulating tumour
cells by RT-PCR (Smith et al, 1991; Burchill et al, 1994; Brown
et al, 1995; Eschwege et al, 1995). The K-ras gene mutation has
been used to detect circulating colorectal cancer cells by an
immunobead-PCR assay, butthis approach is limited because ofthe
low frequency of the gene mutations (30%) in these tumours
(Hardingham et al, 1995). No similar specific mutations are known
forbreast cancer.
We previously reported the detection of tumour cell dissemina-
tion by RT-PCR in a pilot study ofpatients undergoing surgery for
breast cancer by using DF3 (MUCI) antigen mRNA as a molec-
ular marker. The aim ofthe present study was to extend ourearlier
findings and also examine the role ofotherepithelial markers.
The three molecular markers studied were MUC1, cytokeratin
19 (CK19) and CD44 (exons 8-11) mRNA. MUCI and CKl9 are
thought to be specific and sensitive markers of cells of epithelial
origin. The human DF3 breast carcinoma-associated antigen
(MUC1) gene encodes a core protein of human polymorphic
epithelial mucin (PEM) and is uniformly and highly expressed by
malignant human mammary epithelium (Ho et al, 1993). It is
expressed in the tissue of 90% of cases of breast cancer
(Papadimitriou et al, 1993). It has been detected in patients' serum
andhas been shown tobe increased in metastatic disease (Abe and
Kufe, 1993). Cytokeratins are primarily expressed in epithelial
cells (Moll et al, 1982). CK19 has been reported as a specific and
sensitive marker for detection ofbreast carcinoma cells in periph-
eral blood and bone marrow ofpatients with breast cancer by RT-
PCR (Datta et al, 1994). CK19 has been shown to be expressed in
the tissue of 90% of invasive breast cancer (Papadimitriou et al,
1993). We also used CD44 (exons 8-11) as apotential marker, as a
CD44 mRNA variant encoding these sequences has been shown to
be expressed in human colorectal and breast cancer and has been
implicated in the induction of the metastatic phenotype in rat
pancreatic tumourcells (Gunthert etal, 1991; Hofmann etal, 1991;
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Delatorre et al, 1995). CD44 splice variants specific to tumour
cells have been described by Matsumura et al (1992), who
reported that peripheral blood leucocytes contained only the
standard form of CD44 mRNA, although others have reported
traces ofthese splice variants in blood (Fox et al, 1994).
MATERIALS AND METHODS
Cell line
MCF-7 breast carcinoma cells express MUCI (Abe and Kufe,
1993) and CK19 (Moll et al, 1982). This cell line was maintained
in RPMI-1640 (Gibco, Paisley, UK) supplemented with 10% fetal
calf serum. Cells were passaged every 4 days and maintained at
37°C in 5% carbon dioxide.
Blood samples
Peripheral blood samples were obtained from healthy female
volunteers aged between 18 and 48 years. The first 5 ml was
discarded to reduce contamination by epithelial cells at the site of
needle entry. A further 10 ml was then collected in potassium
ethylenediaminetetraacetic acid (EDTA) bottles and promptly
transported to the laboratory at 4°C for immediate processing, as
described by Brown et al (1995).
RNA extraction
In preparation and handling of RNA, scrupulous steps were taken
to avoid degradation by contaminating RNAases. Aerosol-resis-
tant, DNAase- and RNAase-free pipette tips were used atalltimes.
Total cellular RNA was extracted from the MCF-7 cell line and
normal peripheral blood leucocytes using RNAzol B (Biogenesis,
Poole, Dorset, UK) according to the manufacturer's instructions.
The concentration of aqueous solutions of RNA was measured
spectrophotometrically.
Seeding experiments
To assay the sensitivity of the technique, seeding experiments
were carried out by adding varying numbers of MCF-7 cells
(0-106 cells) to 10 ml ofnormal blood. RNA was then extracted as
described above.
RT-PCR
Reverse transcription of RNA and PCR amplification of cDNA
was carried out using RNA-PCR Kit (GeneAmp RNA-PCR kit,
Perkin-Elmer Cetus, Norwalk, CT, USA) after treatment of
samples with RNAase-free DNAase I (Dilworth and McCarrey,
1992). The PCR reaction was carried out in a Perkin-Elmer Cetus
480 DNA thermal cycler; the PCR conditions for each set of
primers are given below. A preceding single cycle was the same
for all sets ofprimers and consisted ofdenaturing cycle at93°C for
5 min, primer annealing at 55-600C for 5 min and polymerization
at 72°C for 15 min.
For MUC 1, the primers used were:
MUCI - 5' primer
5'-CGTCGTGGACATTGATGGTACC-3';
MUCI - 3' primer
5'-GGTACCTCCTCTCACCTCCTCCAA-3'.
The PCR conditions forMUCI were 30 cycles: 93°C for 1 min,
60°C for 1 min and 72°C for 5 min and a final extension cycle at
72°C for 15 min. The MUCI primers produced a 288-bp PCR
product.
For CK19, the primers used were:
CK19 - 5'primer
5'-TTANTGGCAGGTCAGGAGAAGAGCC-3';
CK19 - 3'primer
5'-AGCTAACCATGCAGAACCTCAACGACCGC-3'.
As described by Datta et al (1994) the 3' primer was designed to
preclude transcription ofpseudogenes.
The PCR conditions were40 cycles ofa single round carried out
as described above to yield a 1097-bp PCR product. When two
rounds of PCR were performed, nested primers were used as
described by Datta et al (1994).
For CD44, the primers used were:
CD44(S) - 5' primer
5'-AGTCACAGACCTGCCCAATGCCTTTG-3';
CD44(S) - 3' primer
5'-CACCTTCTTGACTCCCATGTGAGTGT-3';
CD44(exons 8-11) - 5' primer
5'-CTTGGATCCAACCACACCACGGGC1TTGACCACA-3';
CD44(exons 8-11) - 3' primer
5'-CTTGGATCCTTCTTCCTGCTTGATGACCTCGTCCC-3';
CD44(exons 12-14) - 5' primer
5'-ATATGGACTCCAGTCATAGTACAACGCTTCAGC-3';
CD44(exons 12-14) - 3' primer
5'-CTGATAAGGAACGATTGACATTAGAGTTGGAAT-3'.
The PCR conditions were a first round of 20 cycles using
primers to exons 4 and 16 ofCD44, which produces a fragment of
486 bp from the standard form of CD44 mRNA found in leuco-
cytes (Stamenkovic et al, 1989) in which the variant exons 6-15
have been spliced (Screaton et al, 1992). These primers also give
rise to fragments that include the variant exons 6-14. For the
second round of30 cycles, 1-2 gl offirst-round PCR product was
used as atemplate in a 100gl reaction containing eitherthe exon 8
and 11 primers or exon 12 and 14 primers.
For all samples, the quality of RNA was routinely checked by
running the standard form ofCD44(S) as an intemal control. 'No
RT' controls for all RT-PCR reactions were run as above except
that water was substituted for reverse transcriptase. Positive
controls were RNA extracted fromMCF-7 cell lines, and 'negative
controls' contained all components ofthe RT-PCR reaction but no
target RNA template.
Gel electrophoresis of PCR products
RT-PCR products were analysed by 2% agarose gel electro-
phoresis and visualized through staining with ethidium bromide.
A 100-bp DNA ladder or (X174 RF DNA/Hae HI fragments
(Gibco, Paisley, UK) were used as size markers.
Southern blot analysis
PCR products were transferred from ethidium-stained agarose
gels onto a nylon membrane (Hybond N+, Amersham, UK) by
ovemight capillary transfer using 0.4M sodium hydroxide
(Sambrook et al, 1989). Filters were then placed in roller bottles
(Becton Dickinson, Oxford, UK) and prehybridized at 65'C for
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4-6 h in 20 ml of prehybridization buffer containing 6 x SSC
(0.9 M sodium chloride, 0.9 M sodium citrate), 10 x Denhardts
(0.2% (w/v) each ofFicol, polyvinylpyrrolidone and bovine serum
albumin) and 100 ul ml- denatured sonicated salmon sperm DNA.
The prehybridization buffer was then removed and 20 ml of
hybridization fluid added containing 1 x 106 c.p.m. ml- Ofy_32P_
labelled oligonucleotide probe complementary to an internal
sequence in the PCR product for MUCI, and hybridization was
continued for a further 12-18 h. (For CK19 and CD44, the down-
stream primers were used as probes.) Oligonucleotide hybridiza-
tion temperature was calculated from an empirical formula: T = 4
(G or C) + 2 (A or T) - 5°C (Hames and Higgins, 1995). Filters
were then washed at T for 60 min in a buffer containing 6 x SSC,
0.1% sodium dodecyl sulphate (SDS) and for 5 min in the same
buffer at T + 5°C. At the completion of washing, filters were
exposed to radiographic film (Kodak XAR-2 or equivalent) in
cassettes with intensifying screen andexposed at-70°C for 12-36 h.
1 2 3 4 5 6 7
A
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RESULTS
The seeding experiments demonstrated a decreasing signal from
MUC1 mRNA corresponding to a decreasing number of seeded
tumour cells, reflecting an apparent sensitivity of one tumour cell
per ml of blood. However, the unseeded blood sample in lane 1
showed a faint band, casting doubt on the specificity expression of
MUCI mRNA (Figure IA). Further samples of normal peripheral
blood showed variable expression of MUCI mRNA in four of six
volunteers (Figure 1B). A further experiment was performed using
the standard form of CD44 [CD44(S)] mRNA as internal control.
Similar background expression was demonstrated in peripheral
blood samples from healthy human volunteers (Figure IC). This
variation in expression was not due to degradation of RNA in
some specimens, as CD44(S) was equally represented in each
(Figure ID). In total, peripheral blood from 21 of 23 volunteers
showed positive bands when assayed for MUCI mRNA.
The results of the assay for variants of CD44 in peripheral
blood from ten healthy volunteers is depicted in Figure 2. The
metastasis-associated variant (exons 8-11) mRNA is present in
four of ten samples.
In contrast, CK19 mRNA was not detected in normal peripheral
blood (Figure 3). However, under the experimental conditions we
used, the seeding experiments demonstrated that it was impossible
to detect tumour cells at concentrations less than I04 cells per
10 ml ofblood, i.e. one tumour cell per 104 white cells (Figure 4).
This failure ofdetection did not appear to be due to degradation of
RNA, as CD44(S)mRNA was detected in all these samples by RT-
PCR (Figures 3A and 4A). In order to increase the sensitivity of
detection, we attempted to use nested primers as described by
Datta et al (1994), but abandoned this in light of frequency of
detection ofCK19 mRNA in blood from healthy volunteers.
DISCUSSION
We previously reported the results of a pilot study in which we
concluded that DF3 antigen (MUCI) may be used as a specific
marker for detecting circulating tumour cells in patients under-
going surgery for breast cancer. Under similar experimental condi-
tions, we have demonstrated background expression of MUCI in
the peripheral blood of21 of23 healthy human female volunteers.
In support of these findings, Hoon et al (1995) also detected
1 2 3 4 5 6 7
C
D
1 2 3 4 5 6
|4- MUCD
CD44(S)
Figure 1 Sensitivity and specificity of MUC1 mRNA. (A) Autoradiographic
detection of MUC1 mRNA in blood samples from a healthy subject mixed
with serial dilutions of MCF-7 cells after 30 cycles of PCR amplification and
hybridization with 32P-labelled MUC1 oligonucleotide. Lanes 1-6: 0,10, 102,
103, 104 and 105 MCF-7 cells per 10 ml of blood respectively; lane 7, MCF-7
mRNA. (B) Autoradiograph of Southern blot showing hybridization of 32P-
labelled MUC1 oligonucleotide to 30 cycles of PCR product. It demonstrates
288-bp DNAs in the MCF7 mRNA (lane 8) and in four out of six normal
peripheral blood samples (lanes 2-7). Lane 1, 'no RT control. (C) Ethidium
bromide-stained agarose gel of RT-PCR product from MUC1 mRNA in five
other normal bloods (lanes 2-6). Lane 1, 'no RT' control; lane 7, MCF-7
mRNA. (D) Ethidium bromide-stained agarose gel of RT-PCR product for
CD44(S) mRNA as intemal control for the integrity of RNA of all samples of
normal blood and MCF-7 mRNA in Figure 1C
MUCI expression in seven ofeight normal donorperipheral blood
leucocytes and four normal lymph nodes.
Our results also raise serious doubts about the value of using
CD44 (exons 8-11) mRNA to detect circulating tumour cells
because of the frequency with which it is found in normal periph-
eral blood. It is not known whether the expression of these two
markers in normal peripheral blood is due to a small amount of
expression of genes in a proportion of peripheral blood cells, or
due to the presence of a few epithelial cells in the blood of some
individuals.
CK19 mRNA has been claimed to be a specific epithelial cell
marker (Datta et al, 1994). However, the sensitivity ofdetection of
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FIgure 2 Detection of CD44 (exons 8-11) mRNA in normal blood.Ethidium
bromide-stained agarose gel of RT-PCR product for 0044 mRNA showing
expression of exons 8-11 in four out of ten samples of peripheral blood from
healthy volunteers (lanes 4, 5, 8 and 10). The RT-PCR product of exons
12-14 is used here as intemal control. Lane 11, MCF-7 mRNA, lane 12, 'no
RT' control
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Figure 3 Specificity ofCOK19mRNA.(A) Ethidium bromide-stained agarose
gel showing 486-bp bands of 0D44(S) as internal.control for five blood
samples (lanes 2-6) and MCF-7 cells (lane 7). (B) Ethidium bromide-stained
agarose gel of RT-PCR product from CK19 mRNA. Lane 7, MCF-7 mRNA,
lanes 2-6, normal blood samples showing no visible bands. (C) Southern
blot showing hybridization of 2P-labelled OKi9 oligonucleotide to 40 cycles
of PCR product. This shows a 1069-bp band in the MCF-7 cells and confirms
its absence in five normal blood samples. Lane 1, 'no RT' control
CK19 in a single round of amplification was limited to greater
than 104 cells per 10 ml of blood. Because of the frequency with
which CK19 mRNA was detected after two amplification rounds
in blood from healthy volunteers, we abandoned using the nested
primers described by Datta et al (1994), which were designed to
increase sensitivity. We also found increasing the number of
cycles in a single amplification round above 40 cycles enhanced
sensitivity but reduced specificity, as previously reported by
Schoenfield et al (1994).~~~~~~~~~~~
Several repetitions of this experiment produced the same~~~~~~~~~~~~~~~~~~~~. results.The faiure to dtect loer concntration of tumur cell
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Figure 4 Sensitivity of CK19 mRNA. (A) Ethidium bromide-stained agarose
gel showing bands of CD44(S) as internal control for the integrity of RNA.
(B) RT-PCR detection of CK19 mRNA in blood samples from a healthy
subject mixed with serial dilutions of MCF-7 cells detected on ethidium
bromide-stained agarose gel after 40 cycles of PCR amplification.
(C) Southern blot and hybridization of 32P-labelled 0K19 oligonucleotide
to 40 cycles of PCR product of Figure 4B. Lane 1, 'no RT' control; lanes 2-8:
0, 10,102, 103, 104, 105 and 106 MCF-7 cells per 10 ml of blood respectively
did not appear to be due to degradation of RNA, as undegraded
CD44(S) mRNA was detected in these samples by RT-PCR. Our
studies clearly demonstrate that, while RT-PCR has thepotential to
detect minute quantities of a specific RNA sequence against a
background of a vast excess of other RNA, there are dangers in
assuming that the technique can be used to detect minute numbers
of specific cells because of the 'Well-established phenomenon of
illegitimate transcription, which results in very low levels but non-
specific expression of irrelevant genes in many cell types (Chelly
et al, 1989). Illegitimate transcription limits the usefulness of
RT-PCR to detect another putative epithelial cell-specific mRNA
(De Graaf et al, 1997).
The technique of immunobead-PCR may be a solution to the
problem if combined with detection of an irrefutable genetic
marker of a tumour, such as Ki-ras mutations (Hardingham et al,
1993). It may be applicable in those tumours that carry the mutated
gene. Such a specific mutation is as yet unknown in breast cancer.
Further work is essential to identify a suitable epithelial marker
that has the required specificity and sensitivity to be used reliably
in the detection ofcirculating tumour cells from solid tumours, and
meticulous attention to methodology is required to overcome the
technical problems with this method before its broader use in
clinical practice can be recommended.
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